<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>oncology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>oncology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Authors: Hong, J.; Kohutek, Z.; Zhang, H.; Karnoub, E.-R.; Kappagantula, R.; Wood, L. D.; Iacobuzio-Donahue, C.
Score: 9.1, Published: 2024-01-30 DOI: 10.1101/2024.01.30.24301554
We performed WES of 250 unique tumor tissues from 30 multiregion sampled pancreatic cancer research autopsies from patients diagnosed with advanced stage disease. We find that most genetic alterations in PDAC occur in a subclonal manner, and some genes occurred in a subclonal manner exclusively.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/oncology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="oncology" />
<meta property="og:description" content="Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Authors: Hong, J.; Kohutek, Z.; Zhang, H.; Karnoub, E.-R.; Kappagantula, R.; Wood, L. D.; Iacobuzio-Donahue, C.
Score: 9.1, Published: 2024-01-30 DOI: 10.1101/2024.01.30.24301554
We performed WES of 250 unique tumor tissues from 30 multiregion sampled pancreatic cancer research autopsies from patients diagnosed with advanced stage disease. We find that most genetic alterations in PDAC occur in a subclonal manner, and some genes occurred in a subclonal manner exclusively." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/oncology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2024-02-07T10:40:15+00:00" />
<meta property="article:modified_time" content="2024-02-07T10:40:15+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="oncology"/>
<meta name="twitter:description" content="Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer
Authors: Hong, J.; Kohutek, Z.; Zhang, H.; Karnoub, E.-R.; Kappagantula, R.; Wood, L. D.; Iacobuzio-Donahue, C.
Score: 9.1, Published: 2024-01-30 DOI: 10.1101/2024.01.30.24301554
We performed WES of 250 unique tumor tissues from 30 multiregion sampled pancreatic cancer research autopsies from patients diagnosed with advanced stage disease. We find that most genetic alterations in PDAC occur in a subclonal manner, and some genes occurred in a subclonal manner exclusively."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "oncology",
      "item": "https://trxiv.yorks0n.com/posts/oncology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "oncology",
  "name": "oncology",
  "description": "Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer\nAuthors: Hong, J.; Kohutek, Z.; Zhang, H.; Karnoub, E.-R.; Kappagantula, R.; Wood, L. D.; Iacobuzio-Donahue, C.\nScore: 9.1, Published: 2024-01-30 DOI: 10.1101/2024.01.30.24301554\nWe performed WES of 250 unique tumor tissues from 30 multiregion sampled pancreatic cancer research autopsies from patients diagnosed with advanced stage disease. We find that most genetic alterations in PDAC occur in a subclonal manner, and some genes occurred in a subclonal manner exclusively.",
  "keywords": [
    
  ],
  "articleBody": " Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer\nAuthors: Hong, J.; Kohutek, Z.; Zhang, H.; Karnoub, E.-R.; Kappagantula, R.; Wood, L. D.; Iacobuzio-Donahue, C.\nScore: 9.1, Published: 2024-01-30 DOI: 10.1101/2024.01.30.24301554\nWe performed WES of 250 unique tumor tissues from 30 multiregion sampled pancreatic cancer research autopsies from patients diagnosed with advanced stage disease. We find that most genetic alterations in PDAC occur in a subclonal manner, and some genes occurred in a subclonal manner exclusively. Convergent evolution within the TGF{beta} pathway was also identified as a common feature of advanced stage disease, with SMAD4 inactivation more common among metastatic PDACs compared to inactivation of TGF{beta} surface receptors that was more common in locally advanced tumors. The mode of clinical management (radiation versus chemotherapy) contributed distinct mutational signatures yet these mutations are not predicted to have functional relevance to tumor progression. Overall, these findings provide a first definition of the genetic features that distinguish among patients with locally advanced versus metastatic PDAC. These findings may have clinical relevance in upfront clinical decision making for the optimal candidates for neoadjuvant therapy.\nMathematical modeling suggests improved clinical outcomes of second-generation PARP inhibitors with reduced toxicity\nAuthors: Kozlowska, E.; Haltia, U.-M.; Puszynski, K.; Farkkila, A.\nScore: 3.5, Published: 2024-01-30 DOI: 10.1101/2024.01.29.24301918\nHigh-grade serous ovarian cancer (HGSC) is one of the most lethal gynecological cancers. Recent clinical trials have shown the remarkable benefits of maintenance treatment with Poly-ADP Ribose Polymerase inhibitors, particularly in patients with tumors deficient in homologous recombination DNA repair. However, the large Phase III clinical trials are limited in their ability to evaluate various dosages and treatment durations, and the effects of toxicities and treatment interruptions on clinical outcomes remain unknown. In this study, we developed a computational framework for virtual clinical trials taking into account both tumor dynamics (growth selection and evolution of resistance mechanisms) and clinico-pharmacological features (pharmacokinetics, dosing, hematological toxicity, dose interruptions, and reductions). Our model replicates the clinical outcomes observed in the landmark SOLO-1 clinical trial. The branching process model revealed a heterogeneous patient population with distinct tumor dynamics, highlighting fitness and selection pressure as determinants of a poor response. Through a virtual trial approach, we show that managing toxicity via treatment interruptions or dose reductions does not compromise the clinical benefits of the treatment. Importantly, we present evidence that further reduction of hematological toxicity could significantly improve clinical outcomes in first-line PARPi maintenance treatment in ovarian cancer. SignificancePhase III clinical trials are limited in their capacity to investigate different dosing schedules, and the number of participants is relatively small. Furthermore, the effects of toxicities on trial outcomes are frequently unknown. Virtual clinical trials using a mechanistic mathematical model combined with statistical evaluations can overcome these limitations. In this work, we demonstrate the application of a computational framework for optimizing drug scheduling and testing of the next generation of PARP inhibitors, providing insights to guide future clinical trial design.\nNon-invasive multi-cancer diagnosis using DNA hypomethylation of LINE-1 retrotransposons\nAuthors: Michel, M.; Heidary, M.; Mechri, A.; Da Silva, K.; Gorse, M.; von Grafenstein, K.; Hego, C.; Rampanou, A.; Lamy, C.; Kamal, M.; Le Tourneau, C.; Sene, M.; Bieche, I.; Reyes, C.; Gentien, D.; Stern, M.-H.; Lantz, O.; Cabel, L.; Pierga, J.-Y.; Bidard, F.-C.; Azencott, C.-A.; Proudhon, C.\nScore: 4.3, Published: 2024-01-23 DOI: 10.1101/2024.01.20.23288905\nThe detection of circulating tumor DNA, which allows non-invasive tumor molecular profiling and disease follow-up, promises optimal and individualized management of patients with cancer. However, detecting small fractions of tumor DNA released when the tumor burden is reduced remains a challenge. We implemented a new highly sensitive strategy to detect base-pair resolution methylation patterns from plasma DNA and assessed the potential of hypomethylation of LINE-1 retrotransposons as a non-invasive multi-cancer detection biomarker. Resulting machine learning-based classifiers showed powerful correct classification rates discriminating healthy and tumor plasmas from 6 types of cancers in two independent cohorts (AUC = 88% to 100%, N = 747). This should lead to the development of more efficient non-invasive diagnostic tests adapted to all cancer patients, based on the universality of these factors. One-Sentence SummaryLINE-1 retrotransposons hypomethylation is a sensitive and specific biomarker to detect multiple forms of cancer non-invasively.\n",
  "wordCount" : "694",
  "inLanguage": "en",
  "datePublished": "2024-02-07T10:40:15Z",
  "dateModified": "2024-02-07T10:40:15Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/oncology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      oncology
    </h1>
    <div class="post-meta">&lt;span&gt;updated on February 7, 2024&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.30.24301554">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.30.24301554" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.30.24301554">
        <p class="paperTitle">Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.30.24301554" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.30.24301554" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Hong, J.; Kohutek, Z.; Zhang, H.; Karnoub, E.-R.; Kappagantula, R.; Wood, L. D.; Iacobuzio-Donahue, C.</p>
        <p class="info">Score: 9.1, Published: 2024-01-30 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.30.24301554' target='https://doi.org/10.1101/2024.01.30.24301554'> 10.1101/2024.01.30.24301554</a></p>
        <p class="abstract">We performed WES of 250 unique tumor tissues from 30 multiregion sampled pancreatic cancer research autopsies from patients diagnosed with advanced stage disease. We find that most genetic alterations in PDAC occur in a subclonal manner, and some genes occurred in a subclonal manner exclusively. Convergent evolution within the TGF{beta} pathway was also identified as a common feature of advanced stage disease, with SMAD4 inactivation more common among metastatic PDACs compared to inactivation of TGF{beta} surface receptors that was more common in locally advanced tumors. The mode of clinical management (radiation versus chemotherapy) contributed distinct mutational signatures yet these mutations are not predicted to have functional relevance to tumor progression. Overall, these findings provide a first definition of the genetic features that distinguish among patients with locally advanced versus metastatic PDAC. These findings may have clinical relevance in upfront clinical decision making for the optimal candidates for neoadjuvant therapy.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.29.24301918">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.29.24301918" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.29.24301918">
        <p class="paperTitle">Mathematical modeling suggests improved clinical outcomes of second-generation PARP inhibitors with reduced toxicity</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.29.24301918" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.29.24301918" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Kozlowska, E.; Haltia, U.-M.; Puszynski, K.; Farkkila, A.</p>
        <p class="info">Score: 3.5, Published: 2024-01-30 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.29.24301918' target='https://doi.org/10.1101/2024.01.29.24301918'> 10.1101/2024.01.29.24301918</a></p>
        <p class="abstract">High-grade serous ovarian cancer (HGSC) is one of the most lethal gynecological cancers. Recent clinical trials have shown the remarkable benefits of maintenance treatment with Poly-ADP Ribose Polymerase inhibitors, particularly in patients with tumors deficient in homologous recombination DNA repair. However, the large Phase III clinical trials are limited in their ability to evaluate various dosages and treatment durations, and the effects of toxicities and treatment interruptions on clinical outcomes remain unknown. In this study, we developed a computational framework for virtual clinical trials taking into account both tumor dynamics (growth selection and evolution of resistance mechanisms) and clinico-pharmacological features (pharmacokinetics, dosing, hematological toxicity, dose interruptions, and reductions). Our model replicates the clinical outcomes observed in the landmark SOLO-1 clinical trial. The branching process model revealed a heterogeneous patient population with distinct tumor dynamics, highlighting fitness and selection pressure as determinants of a poor response. Through a virtual trial approach, we show that managing toxicity via treatment interruptions or dose reductions does not compromise the clinical benefits of the treatment. Importantly, we present evidence that further reduction of hematological toxicity could significantly improve clinical outcomes in first-line PARPi maintenance treatment in ovarian cancer.

SignificancePhase III clinical trials are limited in their capacity to investigate different dosing schedules, and the number of participants is relatively small. Furthermore, the effects of toxicities on trial outcomes are frequently unknown. Virtual clinical trials using a mechanistic mathematical model combined with statistical evaluations can overcome these limitations. In this work, we demonstrate the application of a computational framework for optimizing drug scheduling and testing of the next generation of PARP inhibitors, providing insights to guide future clinical trial design.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2024.01.20.23288905">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2024.01.20.23288905" aria-expanded="false" aria-controls="flush-collapse10.1101/2024.01.20.23288905">
        <p class="paperTitle">Non-invasive multi-cancer diagnosis using DNA hypomethylation of LINE-1 retrotransposons</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2024.01.20.23288905" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2024.01.20.23288905" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Michel, M.; Heidary, M.; Mechri, A.; Da Silva, K.; Gorse, M.; von Grafenstein, K.; Hego, C.; Rampanou, A.; Lamy, C.; Kamal, M.; Le Tourneau, C.; Sene, M.; Bieche, I.; Reyes, C.; Gentien, D.; Stern, M.-H.; Lantz, O.; Cabel, L.; Pierga, J.-Y.; Bidard, F.-C.; Azencott, C.-A.; Proudhon, C.</p>
        <p class="info">Score: 4.3, Published: 2024-01-23 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2024.01.20.23288905' target='https://doi.org/10.1101/2024.01.20.23288905'> 10.1101/2024.01.20.23288905</a></p>
        <p class="abstract">The detection of circulating tumor DNA, which allows non-invasive tumor molecular profiling and disease follow-up, promises optimal and individualized management of patients with cancer. However, detecting small fractions of tumor DNA released when the tumor burden is reduced remains a challenge. We implemented a new highly sensitive strategy to detect base-pair resolution methylation patterns from plasma DNA and assessed the potential of hypomethylation of LINE-1 retrotransposons as a non-invasive multi-cancer detection biomarker. Resulting machine learning-based classifiers showed powerful correct classification rates discriminating healthy and tumor plasmas from 6 types of cancers in two independent cohorts (AUC = 88% to 100%, N = 747). This should lead to the development of more efficient non-invasive diagnostic tests adapted to all cancer patients, based on the universality of these factors.

One-Sentence SummaryLINE-1 retrotransposons hypomethylation is a sensitive and specific biomarker to detect multiple forms of cancer non-invasively.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2024 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
